The technique of administering the intravitreal injection, and the optimum dosage required to gain a therapeutic benefit still remains a matter of debate. Ozkiris and co-workers administer intravitreal triamcinolone acetonide (IVTA) after performing an anterior chamber paracentesis; in practice, this may be difficult as one is injecting into an already 'soft' eye. However, there seems to be a wide variation in injection technique, and few appear to be evidence-based, as highlighted in a recently published survey. 2 The dosage for several studies looking at the use of IVTA in the treatment of macular oedema in branch retinal vein occlusions is 4 mg, [3] [4] [5] and in one study was 20-25 mg. 6 Ozkiris and co-workers used 8 mg to treat their patients, but the reasoning for this dose is not commented upon. The varying doses administered to patients in different studies can make it difficult to draw any definite conclusions about the appropriate therapeutic dose. A statistically significant improvement in visual acuity (VA) was seen after IVTA, with the maximal response between 1 and 3 months postinjection. This suggests that in order to maintain the best-achieved VA, repeat injections may be necessary. The authors do not comment on whether they would recommend repeat injections, either to maintain the post-treatment improvement in VA in those that responded, or to treat the two cases that were refractory to initial ITVA. In addition, the short follow-up time in this study (6.2 þ /1.0 months) makes it difficult to come to any conclusion about the long-term efficacy of this treatment.
Repeated intravitreal injections are not without risk F the authors did not report any injection-or corticosteroid-related complications. The risk of endophthalmitis is the most feared complication; however, varying problems from conjunctival necrosis to intraocular lens dislocation have been documented with intravitreal injection. 7, 8 In addition, progression of cataract is a well-recognised risk, and it has been suggested that this is related to the number of intravitreal injections administered to a patient. 3 The situation may be further confounded as cataract surgery may aggravate macular oedema in the very eyes that have been treated with repeat injections.
The authors do not discuss their feelings on the statistically significant intraocular pressure (IOP) rise postinjection, except to mention that one eye with a persistently elevated IOP was successfully treated with topical medication. Glaucomatous eyes may not be able to tolerate the increase in IOP postinjection, even if it is within the normal range, and indeed some patients with pre-existing glaucoma may need to be treated by filtration surgery. In addition, after IVTA, that IOP may take as long as 8-9 months to return to preinjection values; 9 this means that patients may have to be on topical treatment for a considerable time, with their attendant side effects.
The exclusion criteria of the study excluded patients if they had diabetes mellitus, presumably owing to either the potential corticosteroid-related complications associated with this intervention or because of any coexisting macular oedema that may have been a confounding factor. However, the authors mention diabetes as a risk factor for branch retinal vein occlusion (BRVO); therefore excluding these patients is excluding a large-patient group from this treatment. It does not have appeared to be part of exclusion criteria in other similar studies, 6 and indeed ITVA used in studies to treat refractory diabetic macular oedema. 10 It seems that IVTA requires further evaluation in relation to its role in the treatment of macular oedema in BRVOs.
